Once weekly Ozempic
Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications or in addition to other medicinal products for the treatment of diabetes.
CV=cardiovascular; CVD=cardiovascular disease; ADA=American Diabetes Association; EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonist. *Results apply to Ozempic® vs placebo, Januvia®, Trulicity®, Bydureon® and Lantus1,2. †In SUSTAIN 6, Ozempic® reduced CV risk (CV death, nonfatal myocardial infarction or nonfatal stroke) versus placebo in patients with type 2 diabetes at high CV risk treated with standard of care.1
References: 1. Ozempic physician leaflet approved by the MOH 2. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. 3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. 4. Bydureon physician leaflet approved by the MOH. 5. Trulicity physician leaflet approved by the MOH.